Newbury Pharmaceuticals AB (NEWBRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Newbury Pharmaceuticals AB (NEWBRY) has a cash flow conversion efficiency ratio of 0.072x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr2.26 Million ≈ $243.21K USD) by net assets (Skr31.30 Million ≈ $3.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Newbury Pharmaceuticals AB market capitalisation for the company's overall valuation and market capitalisation.
Newbury Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Newbury Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Newbury Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Newbury Pharmaceuticals AB ranked by their cash flow conversion efficiency. Explore Newbury Pharmaceuticals AB (NEWBRY) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Skyline Investments Inc
TA:SKLN
|
-0.005x |
|
Union Technologies Informatique Group S.A
PA:FPG
|
-1.424x |
|
Grolleau SAS
PA:ALGRO
|
0.045x |
|
Magontec Ltd
AU:MGL
|
0.008x |
|
Upergy
PA:ALUPG
|
0.129x |
|
Lekoil Limited
F:L5K
|
0.029x |
|
Infobird Co Ltd
NASDAQ:IFBD
|
-0.090x |
|
UNITEDLABELS Aktiengesellschaft
F:ULC
|
0.048x |
Annual Cash Flow Conversion Efficiency for Newbury Pharmaceuticals AB (2021–2024)
The table below shows the annual cash flow conversion efficiency of Newbury Pharmaceuticals AB from 2021 to 2024. View NEWBRY stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-08-31 | Skr51.92 Million ≈ $5.59 Million |
Skr-23.71 Million ≈ $-2.55 Million |
-0.457x | +2.92% |
| 2023-08-31 | Skr49.38 Million ≈ $5.31 Million |
Skr-23.23 Million ≈ $-2.50 Million |
-0.470x | -115.64% |
| 2022-08-31 | Skr68.77 Million ≈ $7.40 Million |
Skr-15.00 Million ≈ $-1.61 Million |
-0.218x | -106.38% |
| 2021-08-31 | Skr38.47 Million ≈ $4.14 Million |
Skr-4.07 Million ≈ $-437.57K |
-0.106x | -- |
About Newbury Pharmaceuticals AB
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.